6814 Share Price Performance
NT$28.00
-2.10 (-6.98%)
Price NT$28.00
Share PriceNT$28.00
Lukas Biomedical Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
6814 Community Narratives
There are no narratives available yet.
Recent 6814 News & Updates
Lukas Biomedical Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.30
- Gross Margin
- 59.06%
- Net Profit Margin
- -53.36%
- Debt/Equity Ratio
- 35.0%
Lukas Biomedical Inc. Competitors
Snowflake Analysis
About 6814
- Founded
- 2002
- Employees
- 96
- CEO
- WebsiteView website
Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. It operates through E-Commerce, Medical Management Business, Cell Products, and Pharmaceutical Market Development segments. The company also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases housing equipment. In addition, the company offers cell reagents; and brand management and consulting services. Lukas Biomedical Inc. was founded in 2002 and is based in New Taipei City, Taiwan.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Taiwanese Market Performance
- 7 Days: 3.8%
- 3 Months: 18.7%
- 1 Year: 17.6%
- Year to Date: 17.4%
Over the last 7 days, the market has risen 3.8%, driven by gains of 5.5% in the Information Technology sector. In contrast, the Healthcare sector is lagging, dropping 3.9%. As for the past 12 months, the market is up 18%. Looking forward, earnings are forecast to grow by 18% annually. Market details ›